RxDoctor Payments Data

David Hensley, MD

Dermatology · Arlington, TXNPI 1144376419

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $349,531 of the $427,623 with a category attached, or 81.7%. 42 manufacturers reported payments, led by Amgen at 32.7% of the total. Reporting peaked in 2023 at $120,358 and has fallen 67.1% since, to $39,543 in 2025. Among dermatology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$427,623in general payments, 2019–2025

Across 1,775 payments — averaging $240.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$140K
  • AbbVie$124K
  • Bristol Myers Squibb$43K
  • Sun Pharmaceutical Industries Inc.$35K
  • Dermavant Sciences, Inc.$34K
  • Lilly USA, LLC$22K
  • plus $30K from 36 others
$182,416in research payments, 2019–2025

Across 126 payments — averaging $1447.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$129K
  • Dermavant Sciences, Inc.$51K
  • Regeneron$3K
  • Novartis$30

What the payments were for

  • Consulting fees$8,6682%
  • Speaking & faculty fees$349,53182%
  • Travel & lodging$29,5257%
  • Food & beverage$39,0919%
  • Education$8080%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen223$139,751
AbbVie(2 entities)405$123,747
Bristol Myers Squibb44$42,766
Sun Pharmaceutical Industries Inc.102$34,954
Dermavant Sciences, Inc.53$33,853
Lilly USA, LLC81$22,248
Organon9$5,677
Johnson & Johnson135$4,264
Ortho Dermatologics, A Division Of Bausch Health US, LLC93$2,927
Novartis82$2,401
Biofrontera Inc.19$2,224
Incyte Corporation36$2,011
Sanofi50$1,473
Regeneron Healthcare Solutions, Inc.54$1,455
UCB, Inc.66$1,305
Galderma Laboratories, L.p.56$1,223
E.r. Squibb & Sons, L.L.C.42$1,138
Mayne Pharma Commercial LLC44$824
Pfizer60$778
Arcutis Biotherapeutics, Inc.17$442
LEO Pharma Inc.22$438
Almirall LLC15$430
Journey Medical Corporation8$228
VYNE Pharmaceuticals Inc.11$193
Strata Skin Sciences, Inc.10$148
Prugen, Inc. Pharmaceuticals6$111
Boehringer Ingelheim5$94
Sanofi-aventis U.S. LLC1$80
Encore Dermatology Inc.4$62
Dermira, Inc.3$58
Sandoz3$46
Medimetriks Pharmaceuticals, Inc.2$34
Aclaris Therapeutics, Inc.2$33
Taro Pharmaceuticals USA, Inc.2$33
Genentech USA, Inc.2$31
Janssen Scientific Affairs, LLC1$31
Merz North America, Inc.1$27
Pierre Fabre Pharmaceuticals, Inc.2$25
Promius Pharma LLC1$20
DUSA Pharmaceuticals, Inc.1$15
Glenmark Therapeutics Inc.1$14
Merck1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$427,623 in reported general payments places this provider in the 95th percentile of 1,098 dermatology providers in Texas.

See all dermatology providers in Texas

Medicare billing

Part B allowed, 2024
$1,032,350
Medicare patients
1,623
Services billed
31,239

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa20$420,895
OtezlaApremilast21$99,558
Humira PenAdalimumab13$88,280
Dupixent PenDupilumab16$59,729
VtamaTapinarof13$18,493
ZoryveRoflumilast14$15,158
Clobetasol Propionate137$6,053
Azelaic Acid44$4,437
Fluocinonide125$4,361
Ketoconazole186$4,343
Triamcinolone Acetonide258$4,058
Doxycycline Hyclate306$3,467
Imiquimod103$3,313
Betamethasone Dipropionate93$3,300
Tacrolimus23$2,741

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$139,751$99,55821 claims
Dermavant Sciences, Inc.Vtama$33,853$18,49313 claims
Arcutis Biotherapeutics, Inc.Zoryve$442$15,15814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,098 dermatology providers in Texas.

Other dermatology in Arlington

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →